RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.19%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$811M
AUM Growth
+$811M
(+9.6%)
Cap. Flow
+$37.6M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10
Top Buys
| 1 |
Becton Dickinson
BDX
|
$16.3M |
| 2 |
CVS Health
CVS
|
$15.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$13.9M |
| 4 |
CELG
Celgene Corp
CELG
|
$12M |
| 5 |
Cigna
CI
|
$10.9M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$15.5M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.5M |
| 3 |
Esperion Therapeutics
ESPR
|
$10.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.14M |
| 5 |
Cencora
COR
|
$6.03M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Technology | 0.23% |
| 3 | Energy | 0.22% |
| 4 | Financials | 0.18% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.5M | 3.51% | 2,007,212 +52,300 | +3% | +$743K |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $26.4M | 3.26% | 296,412 +135,000 | +84% | +$12M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $24.7M | 3.05% | 221,863 +70,000 | +46% | +$7.8M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $24.4M | 3.01% | 150,000 -2,204 | -1% | -$359K |
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $22.4M | 2.76% | 148,436 +15,000 | +11% | +$2.26M |
|
|
ABMD
6
DELISTED
Abiomed Inc
ABMD
| $22.3M | 2.74% | 76,490 -10,000 | -12% | -$2.91M |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $22.1M | 2.73% | 350,000 +220,198 | +170% | +$13.9M |
|
|
8
Nektar Therapeutics
NKTR
$568M
| $22M | 2.72% | 207,458 -146,045 | -41% | -$15.5M |
|
9
Exelixis
EXEL
$10.1B
| $21.8M | 2.69% | 986,214 +230,000 | +30% | +$5.09M |
|
10
AbbVie
ABBV
$372B
| $19.6M | 2.41% | 206,700 +50,000 | +32% | +$4.73M |
|
|
11
Cigna
CI
$80.3B
| $18.5M | 2.28% | 110,400 +65,000 | +143% | +$10.9M |
|
12
Humana
HUM
$36.5B
| $18.3M | 2.25% | 68,000 +10,000 | +17% | +$2.69M |
|
13
Gilead Sciences
GILD
$140B
| $17.9M | 2.2% | 237,027 -48,724 | -17% | -$3.67M |
|
|
14
Esperion Therapeutics
ESPR
$448M
| $17.7M | 2.18% | 244,540 -142,086 | -37% | -$10.3M |
|
15
UnitedHealth
UNH
$281B
| $17.3M | 2.14% | 81,000 +5,500 | +7% | +$1.18M |
|
16
Eli Lilly
LLY
$657B
| $17.2M | 2.13% | 222,859 +80,000 | +56% | +$6.19M |
|
17
Medtronic
MDT
$119B
| $16.9M | 2.09% | 211,283 +47,058 | +29% | +$3.77M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.7M | 2.06% | 792,730 -291,851 | -27% | -$6.14M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $16.6M | 2.05% | 204,849 +65,000 | +46% | +$5.27M |
|
|
20
Becton Dickinson
BDX
$55.3B
| $16.3M | 2% | +75,000 | New | +$16.3M |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $16M | 1.97% | 944,185 | – | – |
|
|
22
CVS Health
CVS
$92.8B
| $15.8M | 1.95% | +253,868 | New | +$15.8M |
|
23
Glaukos
GKOS
$5.5B
| $15.5M | 1.91% | 503,400 -105,000 | -17% | -$3.24M |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $15.3M | 1.89% | 95,000 -9,930 | -9% | -$1.6M |
|
|
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
| $14.9M | 1.83% | 215,000 -6,483 | -3% | -$448K |
|